Deep-pocketed investors have adopted a bullish approach towards Edwards Lifesciences EW, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in EW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Edwards Lifesciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 64% leaning bullish and 14% bearish. Among these notable options, 6 are puts, totaling $403,470, and 8 are calls, amounting to $528,444.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $72.5 for Edwards Lifesciences over the last 3 months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Edwards Lifesciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Edwards Lifesciences's substantial trades, within a strike price spectrum from $50.0 to $72.5 over the preceding 30 days.
Edwards Lifesciences Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EW | CALL | TRADE | BEARISH | 01/17/25 | $2.7 | $2.5 | $2.55 | $72.50 | $178.2K | 33 | 801 |
| EW | PUT | TRADE | BEARISH | 01/17/25 | $4.5 | $4.2 | $4.5 | $60.00 | $135.0K | 1.2K | 300 |
| EW | PUT | TRADE | BULLISH | 01/17/25 | $4.4 | $4.1 | $4.2 | $60.00 | $126.0K | 1.2K | 600 |
| EW | CALL | SWEEP | BULLISH | 11/15/24 | $2.7 | $2.45 | $2.6 | $70.00 | $94.6K | 100 | 502 |
| EW | CALL | TRADE | BULLISH | 01/17/25 | $6.7 | $6.5 | $6.7 | $62.50 | $53.6K | 98 | 1 |
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Current Position of Edwards Lifesciences
- Trading volume stands at 8,101,822, with EW's price up by 4.18%, positioned at $62.2.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 89 days.
Expert Opinions on Edwards Lifesciences
In the last month, 5 experts released ratings on this stock with an average target price of $76.4.
- An analyst from TD Cowen has revised its rating downward to Hold, adjusting the price target to $70.
- An analyst from Baird downgraded its action to Neutral with a price target of $70.
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Edwards Lifesciences, targeting a price of $85.
- An analyst from Truist Securities has revised its rating downward to Hold, adjusting the price target to $82.
- An analyst from B of A Securities downgraded its action to Neutral with a price target of $75.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Edwards Lifesciences options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
